-
1 Comment
Vascular Biogenics Ltd is currently in a long term uptrend where the price is trading 13.4% above its 200 day moving average.
From a valuation standpoint, the stock is 92.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 102.8.
Vascular Biogenics Ltd's total revenue rose by 62.7% to $205K since the same quarter in the previous year.
Its net income has dropped by 26.7% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 96.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Vascular Biogenics Ltd gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | IL0011327454 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 12M |
|---|---|
| Target Price | 5 |
| PE Ratio | None |
| Beta | 0.71 |
| Dividend Yield | 0.0% |
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VBLT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
